The antidiabetic and hepatoprotective effects of myricitrin on aged mice with D-galactose.

Abstract

The present study aims to evaluate the effects of antidiabetic and hepatoprotective of myricitrin in the aged mice induced by D-galactose (D-gal). Aging occurs during a person's life; there has been no way to stop the aging process, but antioxidant and changing lifestyles can delay it. In this experimental study, 72 female adult mice (weighing30-35g) were randomly divided into six groups: 1: control, 2: D-gal at 500mg/kg/d, 3-5: D-gal+ Myricitrin at 5, 10 and 20mg/kg/d 6: D-gal+ Vitamin E at 100mg/kg/d. Aging induced by D-gal for 45 days via intraperitoneal. Myricitrin and Vitamin E administrated orally by gavage for the last 28 days. The blood glucose, insulin level, β-cell function, insulin resistance, hepatic enzymes, lipid profile, and histology of the liver, and pancreas were evaluated. D-gal injection increased the glucose (p<0.001) and insulin levels (p<0.01) compared to control group. Myricitrin (p<0.01) and Vitamin E (p<0.001) increased insulin and decreased blood glucose levels compared to D-gal group. Myricitrin had a similar impact on insulin levels to vitamin E. Insulin resistance induced in the D-gal group (p<0.001). Myricitrin reduced insulin resistance and increased β-cell function (p<0.01) compared to D-gal group. D-gal elevated (p<0.01) cholesterol, LDL and triglyceride level, myricitrin (p<0.001), and Vitamin E (p<0.05) were reduced. D-gal-induced aging causes the accumulation of RBCs, inflammation in the liver, and changes in the number and diameter of Langerhans islets in the pancreas. Myricitrin improved these D-gal effects. Myricitrin had the anti-diabetic and hepatoprotective effects on the aged mice induced by D-galactose.